期刊文献+

苯甲酸阿格列汀联合二甲双胍对糖尿病的治疗效果观察 被引量:2

下载PDF
导出
摘要 目的将苯甲酸阿格列汀和二甲双胍联合应用于糖尿病患者中,观察及评估其治疗效果。方法 80例2型糖尿病患者,依据治疗用药不同分为参照组与实验组,各40例。参照组给予阿卡波糖和二甲双胍联合治疗,实验组给予苯甲酸阿格列汀和二甲双胍联合治疗。比较两组患者的治疗效果、低血糖及轻微胃肠道不良反应发生情况。结果实验组患者治疗总有效率95.00%高于参照组的77.50%,差异具有统计学意义(P<0.05)。实验组患者轻微胃肠道不良反应发生率5.00%低于参照组的7.50%,但差异无统计学意义(P>0.05)。实验组患者低血糖发生率2.50%低于参照组的15.00%,差异具有统计学意义(P<0.05)。结论糖尿病患者采取苯甲酸阿格列汀和二甲双胍联合治疗具有较优疗效。
出处 《中国实用医药》 2018年第25期126-127,共2页 China Practical Medicine
  • 相关文献

参考文献8

二级参考文献64

  • 1周鹏,西琳.玉努斯,周歆理,葛娟,关黎清,邢清海,孙建秀,张燕,叶尔肯.多森拜克.不同糖耐量人群胰岛素抵抗和胰岛B细胞分泌功能的临床研究[J].中国综合临床,2006,22(9):782-784. 被引量:3
  • 2彭娟,胡秀文,高丹宇,李文强,安洁,李鹏,舒玲.复方樟柳碱注射液在眼科的临床应用[J].国际眼科杂志,2007,7(4):1124-1127. 被引量:75
  • 3White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes [ J]. N Engl J Meal,2013,369(14) :1327-1335.
  • 4Xu Y,Wang L,He J,et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA,2013,310(9) :948-959.
  • 5Holst JJ. The physiology of glucagon-like peptide 1 [ J] . Physiol Rev,2007,87:1409-1439.
  • 6Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1receptor agonists and dipeptidyl peptidase~4 inhibitors in type 2 diabetes[J]. Lancet, 2006,368: 1696-1705.
  • 7Marre M,Shaw J, Bfandle M, et al. Liraglutide, a once-daily humanGLP-1 analogue, added to a sulphonylurea over 26 weeks producesgreater improvements in glycaemic and weight control compared withadding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1SU)[J]. Diabet Med, 2009,26:268-278.
  • 8Nauck M, Frid A, Hermnsen K, et al. Efficacy and safety comparisonof liraglutide, glimepiride, and placebo, all in combination withmetformin, in type 2 diabetes : the LEAD (liraglutide effect and actionin diabetes) -2 study [ J] . Diabetes Care, 2009,3 :84-90.
  • 9Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiridemonotherapy for type 2 diabetes( LEAD-3 Mono): a randomised, 52-week ,phase III,double-blind,paralleltreatment trial [ J ]. Lancet,2009,373:473481.
  • 10Zinman B,Gerich J, Buse JB,et al. Efficacy and safety of the humanglucagon-like peptide-1 analog liraglutide in combination withmetformin and thiazolidinedione in patients with type 2 diabetes ( LEAD-4 MET+TZD) [J]. Diabetes Care, 2009 ,32 : 1224-1230.

共引文献94

同被引文献24

引证文献2

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部